Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASCEND-JC: A Multi-center, Randomized, Double-blind, Phase 2 Study, Evaluating JCPyV-specific T Cell Therapy for the Treatment of PML

NCT05541549 is registered in ClinicalTrials.gov with Cellevolve Bio Inc as lead sponsor.

NCT NCT05541549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05541549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASCEND-JC: A Multi-center, Randomized, Double-blind, Phase 2 Study, Evaluating JCPyV-specific T Cell Therapy for the Treatment of PML
Lead sponsor
Cellevolve Bio Inc
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2023
Completion date
April 30, 2025
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

progressive multifocal leukoencephalopathy